Internal Medicine, Hematology & Oncology · Encinitas, CA
NPI
1912260829
Since 2012
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
0
Hospital affiliations
326 Santa Fe Dr Ste 105
Encinitas, CA, 92024
Phone (760) 452-3340
Groups this clinician bills Medicare through
Medicare paid, 2024
$817K
24,034 services
Medicare patients, 2024
86
Average age 71
Drug cost, 2024
$5.3M
1,716 prescriptions
Company payments, 2025
$4,008
From 40 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John P Schwerkoske was code 96413 (chemotherapy administration), 94 times for 15 patients. In total John P Schwerkoske billed 24,034 services in 66 codes, and Medicare paid $817K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 96413 Chemotherapy Administration | Office | 94 | 15 | $113.94 | $11K |
| 99214 Office E&M - Established | Office | 77 | 37 | $94.21 | $7,254 |
| 99213 Office E&M - Established | Office | 48 | 37 | $70.12 | $3,366 |
| 96372 Injection Administration | Office | 19 | 13 | $12.50 | $238 |
By year: 2022 $150K for 10,901 services; 2023 $435K for 28,270 services; 2024 $817K for 24,034 services.
Medicare prescription drug claims, 2024
In 2024, the drug John P Schwerkoske prescribed most often to Medicare patients was Anastrozole, with 220 prescriptions and refills. In total John P Schwerkoske wrote 1,716 Medicare prescriptions that cost $5.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 220 | 525 | 76 | $3,955 |
| Letrozole Generic | 113 | 271 | 34 | $1,792 |
| Alendronate Sodium Generic | 66 | 174 | 26 | $455 |
| Famotidine Generic | 54 | 68 | 26 | $417 |
| Ondansetron Hcl Generic | 51 | 51 | 32 | $1,078 |
| Hydroxyurea Generic | 44 | 96 | 14 | $1,871 |
| Pantoprazole Sodium Generic | 42 | 54 | 22 | $137 |
| Dexamethasone Generic | 38 | 45 | 19 | $604 |
| Eliquis Apixaban | 38 | 46 | 11 | $26K |
| Keytruda Pembrolizumab | 34 | 34 | Under 11 | $365K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 33 | 35 | 17 | $824 |
| Exemestane Generic | 32 | 50 | 11 | $6,193 |
| Inlyta Axitinib | 31 | 31 | Under 11 | $651K |
| Erleada Apalutamide | 31 | 31 | Under 11 | $463K |
| Prochlorperazine Maleate Generic | 28 | 28 | 19 | $248 |
Brand drugs: 446 claims; generic drugs: 1,270 claims; opioid claims: 77.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John P Schwerkoske $4,008 ($4,008 in general payments such as food, travel and fees) from 40 companies. The largest payer was Novartis Pharmaceuticals Corporation with $885.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 17 | $885 |
| Celgene Corporation BMY | 16 | $275 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 5 | $245 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $235 |
| Karyopharm Therapeutics Inc. KPTI | 7 | $216 |
| E.R. Squibb & Sons, L.L.C. BMY | 12 | $198 |
| Sumitomo Pharma America, Inc. 4506.T | 5 | $181 |
| Pfizer Inc. PFE | 6 | $139 |
| Sobi, Inc SOBI.ST | 4 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 3 | $112 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.